

# Patricia E Fast

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2390116/publications.pdf>

Version: 2024-02-01

42  
papers

2,024  
citations

471509

17  
h-index

276875

41  
g-index

43  
all docs

43  
docs citations

43  
times ranked

2640  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cohort Profile: IAVI's HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery. <i>International Journal of Epidemiology</i> , 2021, 50, 29-30.	1.9	11
2	Response to: "Inclusion as Illusion: Erasing Transgender Women in Research with MSM". <i>Journal of the International AIDS Society</i> , 2021, 24, e25662.	3.0	2
3	Use of propensity score matching to create counterfactual group to assess potential HIV prevention interventions. <i>Scientific Reports</i> , 2021, 11, 7017.	3.3	5
4	HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use. <i>Lancet HIV</i> , 2020, 7, e141-e148.	4.7	2
5	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines. <i>Vaccine</i> , 2020, 38, 6184-6189.	3.8	6
6	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. <i>Vaccine</i> , 2020, 38, 5734-5739.	3.8	6
7	Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. <i>Vaccine</i> , 2020, 38, 7702-7707.	3.8	6
8	Involvement of African men and transgender women who have sex with men in HIV research: progress, but much more must be done. <i>Journal of the International AIDS Society</i> , 2020, 23, e25596.	3.0	13
9	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. <i>Vaccine</i> , 2020, 38, 5556-5561.	3.8	9
10	Understanding mobility and sexual risk behaviour among women in fishing communities of Lake Victoria in East Africa: a qualitative study. <i>BMC Public Health</i> , 2020, 20, 944.	2.9	18
11	Comparison of HIV Risk Behaviors Between Clinical Trials and Observational Cohorts in Uganda. <i>AIDS and Behavior</i> , 2020, 24, 2872-2884.	2.7	1
12	Comparison of retention in observational cohorts and nested simulated HIV vaccine efficacy trials in the key populations in Uganda. <i>BMC Medical Research Methodology</i> , 2020, 20, 32.	3.1	4
13	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. <i>Vaccine</i> , 2020, 38, 7708-7715.	3.8	4
14	Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda. <i>Vaccine</i> , 2019, 37, 2065-2072.	3.8	14
15	Use of reliable contraceptives and its correlates among women participating in Simulated HIV vaccine efficacy trials in key-populations in Uganda. <i>Scientific Reports</i> , 2019, 9, 15418.	3.3	3
16	Retention of adults from fishing communities in an HIV vaccine preparedness study in Masaka, Uganda. <i>PLoS ONE</i> , 2019, 14, e0198460.	2.5	15
17	Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: Implications for sample size estimates. <i>Vaccine</i> , 2016, 34, 1778-1785.	3.8	26
18	Canine distemper virus neutralization activity is low in human serum and it is sensitive to an amino acid substitution in the hemagglutinin protein. <i>Virology</i> , 2015, 482, 218-224.	2.4	11

#	ARTICLE	IF	CITATIONS
19	An influenza vaccine pillâ€”can we swallow it?. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 992-993.	9.1	0
20	Creating an African HIV Clinical Research and Prevention Trials Network: HIV Prevalence, Incidence and Transmission. <i>PLoS ONE</i> , 2015, 10, e0116100.	2.5	43
21	High Transmitter CD4+ T-Cell Count Shortly after the Time of Transmission in a Study of African Serodiscordant Couples. <i>PLoS ONE</i> , 2015, 10, e0134438.	2.5	2
22	Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 714-723.	3.3	8
23	WHO's new guidelines for antiretroviral treatment. <i>Lancet</i> , The, 2013, 382, 1778-1779.	13.7	6
24	Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa. <i>Aids</i> , 2013, 27, 2775-2786.	2.2	90
25	Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 630-638.	3.3	4
26	In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. <i>PLoS ONE</i> , 2011, 6, e19252.	2.5	160
27	HIV vaccines: current status worldwide and in Africa. <i>Aids</i> , 2010, 24, S50-S60.	2.2	14
28	Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine. <i>PLoS ONE</i> , 2010, 5, e8617.	2.5	41
29	Ensuring quality of services in HIV prevention research settings: findings from a multi-center quality improvement pilot in East Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 119-125.	1.2	8
30	Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine. <i>PLoS ONE</i> , 2010, 5, e8816.	2.5	47
31	Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa. <i>PLoS ONE</i> , 2010, 5, e12873.	2.5	86
32	Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm. <i>Journal of Virology</i> , 2009, 83, 7337-7348.	3.4	538
33	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1107-1116.	1.1	53
34	CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa. <i>PLoS ONE</i> , 2009, 4, e4401.	2.5	139
35	Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. <i>Vaccine</i> , 2008, 26, 2788-2795.	3.8	83
36	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 873-880.	1.1	43

#	ARTICLE	IF	CITATIONS
37	A strategy for accelerating the development of preventive AIDS vaccines. <i>Aids</i> , 2007, 21, 2259-2263.	2.2	16
38	Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. <i>Vaccine</i> , 2007, 25, 2120-2127.	3.8	96
39	Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. <i>Vaccine</i> , 2006, 24, 417-425.	3.8	117
40	Recent trends in clinical trials of vaccines to prevent HIV/AIDS. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 267-271.	3.8	7
41	Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8 + T-Cell Epitopes. <i>Journal of Virology</i> , 2006, 80, 4717-4728.	3.4	220
42	Preventing Discrimination Against Volunteers in Prophylactic HIV Vaccine Trials: Lessons From a Phase II Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 519-526.	0.3	46